SPOTLIGHT -
Dr. Romancik on Maximizing CAR T-cell Therapy in NHL
Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.
Read More
Dr. Romancik on the Benefit of Second-line Axi-cel in R/R DLBCL
Jason Romancik, MD, discusses the benefit of axicabtagene ciloleucel vs standard of care as a second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.
Dr. Romancik on the Phase 2 PILOT Study of Liso-Cel in Aggressive B-Cell NHL
Jason Romancik, MD, discusses the design and key results from the phase 2 PILOT study.
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
